Thyroid cancer is the most common endocrine malignancy. Differentiated thyroid cancer
(DTC) with the two subtypes, papillary thyroid cancer (PTC) and follicular thyroid cancer …

Incretin‐based therapies, such as the injectable glucagon‐like peptide‐1 (GLP‐1) receptor
agonists and orally administered dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have recently …

Context: European studies have shown that the use of routine calcitonin screening for
detection of medullary thyroid cancer (MTC) in patients with thyroid nodules increases the …

Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate a patient with a new diagnosis of medullary thyroid cancer. Use genetic testing for …

The rapid technical advances in molecular biology and accelerating improvements in
genomic and proteomic diagnostics have led to increasingly personalized strategies for …

Abstract On April 6, 2011, the US Food and Drug Administration approved vandetanib
(Caprelsa tablets; AstraZeneca Pharmaceuticals LP) for the treatment of symptomatic or …

Medullary thyroid carcinoma (MTC), arising from the parafollicular C cells of the thyroid,
accounts for 1–2% of thyroid cancers. MTC is frequently aggressive and metastasizes to …

Thyroid cancer is an increasingly prevalent malignancy throughout the world. Management
guidelines for both thyroid nodules and thyroid cancer have been published and updated by …

This manuscript investigates cabozantinib, vandetanib, pralsetinib, and selpercatinib, four
tyrosine kinase inhibitors (TKIs), which are used to treat advanced and/or metastatic …

Background The primary aim of this study was to evaluate the therapeutic efficacy and
outcome of 177Lu‐DOTATATE peptide receptor radionuclide therapy (PRRT) in …